Crestwood Advisors Group’s Nektar Therapeutics NKTR Stock Holding History

Crestwood Advisors Group’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-67	Closed	-$19K	–	342
2017 Q1	$19K	Buy	+67	New	+$15.1K	﹤0.01%	382

Other funds holding NKTR

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Crestwood Advisors Group's NKTR Position: Q2 2017 in Review

Crestwood Advisors Group sold out of Nektar Therapeutics (NKTR) in Q2 2017, closing a stake of 67 shares — an estimated $19K sold.

Crestwood Advisors Group first reported a position in NKTR in Q1 2017 and held it in 1 quarter. The position peaked at $19K in Q1 2017. 197 funds tracked by Wall St. Rank hold NKTR as of Q2 2017.

Crestwood Advisors Group reported no remaining Nektar Therapeutics position as of Q2 2017 after selling out during the quarter.
Crestwood Advisors Group sold 67 Nektar Therapeutics shares in Q2 2017, an estimated $19K.
Crestwood Advisors Group first reported a position in Nektar Therapeutics in Q1 2017 and held it in 1 quarter.
Crestwood Advisors Group's Nektar Therapeutics position peaked at $19K in Q1 2017.
197 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2017.

Based on Crestwood Advisors Group's 13F filing for Q2 2017, filed 31 Jul 2017.